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Background: Studying DNA methylation profiles in detail should be the first step in epigenetic research. Although
sodium bisulfite modification of genomic DNA is the gold standard method for DNA methylation analysis,
this method results in the loss of the majority of the DNA material. Whole genome amplification (WGA) of
bisulfite-modified DNA is expected to provide a rich source of materials, but its validity has not been thoroughly
evaluated. In this study, we evaluated the extent of biased amplification in the WGA of bisulfite-modified DNA and
the reproducibility of independent WGA reactions. We performed the multiple displacement amplification-based
WGA separately three times. Each experiment included two reactions using 10 or 50 ng of bisulfite-modified DNA
as template. DNA methylation levels were compared between WGA products and original bisulfite-modified DNA at
about 450,000 CpG sites.
Results: Using a sufficient amount of bisulfite-modified DNA for WGA was critical for downstream application. The
considerable deviations from original bisulfite-modified DNA were found in the middle range of DNA methylation
levels. Distribution of hyper- and hypomethylation were equal, which suggested that the deviation at each CpG site
occurred randomly. Averaging the data from independently amplified WGA products dramatically improved the
overall quality.
Conclusions: WGA of bisulfite-modified DNA could be a valuable tool for epigenetic research, but careful
experimental design and data interpretation are required.
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In mammals, DNA methylation is mainly observed at
the cytosine residues of CpG dinucleotides. The methyl
group is transferred to the fifth position of cytosine by
DNA methyltransferases. This modification plays im-
portant roles in the regulation of gene expression [1]. In
the promoter region, where a CpG-rich region known as
the CpG island is often situated, DNA methylation is
generally involved in gene silencing. In the intragenic
regions, where most of the methylcytosine is enriched,
DNA methylation is associated with highly expressed
genes and alternative splicing, although its precise role
remains unclear [2-5].
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reproduction in any medium, provided the orexpression. Alteration of the DNA methylation results in
developmental deficits and diseases [1,6]. Studies have
shown that, in addition to cancer, various kinds of dis-
eases, such as autoimmune diseases, diabetes, and
neuropsychiatric diseases, are associated with altered
DNA methylation [6-8]. Detailed qualitative and quanti-
tative analyses of DNA methylation profiles should be
the first step of epigenetic research in clinical medicine.
Sodium bisulfite modification of genomic DNA, which
converts non-methyl cytosine to uracil, has been the
gold standard method for DNA methylation analysis for
decades. However, this method causes the degradation
of genomic DNA, resulting in a loss of the majority of
DNA material. Therefore, the amount of DNA required
for such analyses is often on the order of micrograms.
Whole genome amplification (WGA) has been used to
amplify genomic DNA for sequencing and genotyping
analyses [9-11]. This method may also be valuable for
epigenetic research, as WGA could provide a largeLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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Figure 1 Schematic diagram of the experimental design.
Genomic DNA extracted from peripheral blood was used for sodium
bisulfite modification. Either 10 or 50 ng of bisulfite-modified DNA
was used for multiple displacement amplification (MDA)-based
whole genome amplification (WGA). We performed three
independent WGA experiments. In each experiment set, deionized
distilled water (DDW) was included as a negative control. Note that
after bisulfite modification, DNA is in a single-stranded form.
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methylation during amplification, bisulfite-modified
DNA must be used as the template for WGA. One
expected challenge is the unbiased amplification of
bisulfite-modified genome DNA, which shows reduced
genome complexity. In addition, unlike conventional
genotyping, which is basically represented as categorical
values (two homozygous alleles and one heterozygous
allele), methylation levels are represented as continuous
values ranging from 0 to 100%. It will be important,
therefore, to develop a precise quantitative assay using
WGA products, as well as a strategy for appropriate data
interpretation.
Previous studies have reported on the validity and lim-
itations of the application of WGA to bisulfite-modified
genomic DNA [12-15], but only a handful of CpG sites
were evaluated. Therefore, the extent of biased amplifi-
cation in the WGA products and reproducibility of inde-
pendent WGA reactions at the genome-wide level
remain largely unclear, as does the effect of the quantity
of starting materials. In this study, we systematically
examined the validity and limitations of the WGA of
bisulfite-modified genomic DNA.
Results
Whole genome amplification of bisulfite-modified DNA
We performed multiple displacement amplification
(MDA)-based WGA by phi29 DNA polymerase using
sodium bisulfite-modified DNA as the template. A sche-
matic diagram of the experimental design is shown in
Figure 1. To focus on the evaluation of WGA, bisulfite-
modified DNA was prepared from genomic DNA
derived from one subject, and all experiments were per-
formed using an identical batch for bisulfite treatment.
The WGA experiments were replicated three times.
Each experiment includes three WGA reactions (10 or
50 ng of bisulfite-modified DNA as template, and deio-
nized distilled water (DDW) as a negative control). Irre-
spective of the quantity of bisulfite-modified DNA, we
obtained about 4 to 6 μg of amplified products (Table 1),
whereas we did not observe significant amplification
from negative controls. Agarose gel electrophoresis
revealed no remarkable differences in product size
across all WGA products (data not shown).
Genome-wide DNA methylation profiling of whole
genome amplification products
We performed an Infinium HumanMethylation450
assay, which evaluates DNA methylation levels of about
450,000 CpG sites, using WGA products of bisulfite-
modified DNA and original bisulfite-modified DNA. The
total number of reliably detected CpG sites was signifi-
cantly decreased after WGA, and depended on the
quantity of bisulfite-modified DNA used for WGAreaction (Table 1). Average signal intensities of both
methylation and unmethylation probes were also con-
cordantly decreased in the WGA products (Table 1).Clustering and principal component analysis of whole
genome amplification products
Consistent with the lower number of detected CpG and
decreased signal intensities in the WGA products, clus-
tering analysis and principal component analysis clearly
revealed that each WGA product of bisulfite-modified
DNA showed a large deviation from original bisulfite-
modified DNAs in a quantity-dependent manner
(Figure 2a,b).Pairwise correlation
We calculated pairwise correlations of the methylation
profile between all possible pairs (Figure 2c). Whereas
correlations among original bisulfite-modified DNAs
were very high (R = 0.991 to 0.992), Those correlations
between original bisulfite-modified DNAs and WGA
products decreased progressively according to the quan-
tity of bisulfite-modified DNA, ranging from R = 0.923
to 0.935 for 50 ng and from R = 0.855 to 0.865 for
10 ng. Likewise, the average correlation among tripli-
cates also decreased and was dependent upon the quan-
tity of bisulfite-modified DNA (average R = 0.911 and
0.826 for 50 and 10 ng, respectively).
Table 1 Yield and overall quality of whole genome amplification (WGA) products of bisulfite-modified DNA
Sample WGA yield (ng) Number of the detected CpGa Average methylation signal Average unmethylation signal
no amplification 1 - 484,857 (99.81 %) 1,764.202 2,537.532
no amplification 2 - 484,841 (99.81 %) 1,967.142 2,682.317
no amplification 3 - 484,831 (99.81 %) 1,882.296 2,875.583
WGA 50 ng 1 4,400 480,869 (98.99 %) 1,262.738 2,584.268
WGA 50 ng 2 6,000 480,159 (98.85 %) 1,266.639 2,113.009
WGA 50 ng 3 4,680 479,465 (98.70 %) 1,354.389 2,347.615
WGA 10 ng 1 4,300 465,730 (95.88 %) 1,208.001 2,257.573
WGA 10 ng 2 6,260 463,572 (95.43 %) 1,082.716 2,190.567
WGA 10 ng 3 6,020 467,036 (96.14 %) 1,292.537 1,931.764
DDW1 68 - - -
DDW2 58 - - -
DDW3 14 - - -
aDetection P value below 0.01 considered significant detection.
WGA, whole genome amplification; DDW, deionized distilled water.
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We arbitrarily chose one original bisulfite modified
DNA as a reference sample and calculated the correl-
ation and beta value difference from those of other pro-
ducts (Figure 3). A beta value was calculated as the ratio
of fluorescent signal intensity of the methylated probe to
those of total (methylated and unmethylated) probes,
and was considered as a DNA methylation level. The
correlations were maintained at relatively high levels
even in the WGA products using 10 ng of bisulfite-
modified DNA (Figures 2 and 3). However, scatter plotsBS (no WGA)WGA 50 ngWGA 10
BS_1 BS_2 BS_3 50ng_
BS_1 1
BS_2 0.992 1
BS_3 0.991 0.992 1
WGA_50ng_1 0.935 0.934 0.935 1
WGA_50ng_2 0.928 0.926 0.926 0.914
WGA_50ng_3 0.924 0.923 0.923 0.911
WGA_10ng_1 0.865 0.863 0.864 0.865
WGA_10ng_2 0.856 0.854 0.855 0.859




Figure 2 Unbiased hierarchical clustering analysis (a), principal comp
genome amplification (WGA) products of bisulfite-modified DNA. Theclearly showed considerable deviations, especially in the
middle range of beta values (from 0.3 to 0.7). A histo-
gram of the beta value difference from the reference
revealed that deviations in the WGA products were uni-
formly distributed in both directions (that is, hyper- and
hypomethylation) (Figure 4). Whereas 99% of the total
probes showed a beta value difference between 0.1 and
−0.1 among the triplicates of original bisulfite-modified
DNAs, only 78% and 65% of the total probe were
included in this range for WGA products using 50 and
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onent analysis (b), and pairwise correlation analysis (c) of whole
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Figure 3 Scatter plot of beta values between reference sample and whole genome amplification (WGA) products.
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We then examined the beta value difference with re-
gard to methylation levels of the reference sample
(Figure 5). In contrast to original bisulfite-modified
















-0.5 to -0.4 -0.4 to -0.3 -0.3 to -0.2 -0.2 to -0.1 -0.1 to 0
Figure 4 Distribution of beta value deviations from the reference samrange of beta values, the WGA products showed
considerable deviations, especially in the middle
range of beta values. At the level of 50% methyla-
tion, the average ± standard deviation beta value dif-
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Figure 5 Beta value differences with regard to methylation level. The absolute beta value difference between whole genome amplification
(WGA) product and the reference sample was calculated for each probe. Probes were divided into ten groups based on beta values of the




















Figure 6 Validation of extent of standard deviation by
pyrosequencing. A total of four CpG sites (see Table S1 in
Additional file 1 for detail) were selected for analysis. In each CpG
site, DNA methylation levels were measured by pyrosequencing at
two different amounts of input DNA (50 ng and 10 ng) in triplicate.
Standard deviations determined by Illumina assay and
pyrosequencing were plotted.
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DNA, respectively.
Validation of Illumina DNA methylation data
by pyrosequencing
We arbitrary chose the CpG sites showing various
degrees of standard deviation (SD) of beta values after
WGA (see Table S1 in Additional file 1). We then deter-
mined DNA methylation levels at each CpG site using
pyrosequencing. The correlation between Illumina assay
and pyrosequencing was very high (R = 0.921). Standard
deviations determined by pyrosequencing showed con-
sistent results with those determined by the Illumina
assay (R = 0.900) (Figure 6).
Effect of averaging the multiple WGA products
Given that amplification biases occurred randomly
(Figure 4), we expected that averaging multiple WGA
products would reduce the deviations. In fact, averaging
the triplicate experimental data considerably improved
amplification biases in WGA products of both 50 ng
(R = 0.950) and 10 ng (R = 0.902) of bisulfite-modified
DNA (Figure 7a). Consistency of the middle-range methy-
lation levels was also markedly improved. At the level of
50% methylation, the average ± standard deviation beta
value differences were 0.088 ± 0.071 and 0.131 ± 0.097 for
WGA products of 50 and 10 ng of bisulfite-modified
DNA, respectively (Figure 7b).
Discussion
We examined the characteristics of MDA-based WGA
of bisulfite-modified genomic DNA in detail. First, our
analyses revealed that when performing WGA, using asufficient amount of bisulfite-modified genome DNA is
critical. Comparison between WGA products using 50
or 10 ng of bisulfite-modified DNA clearly showed more
deviations in the 10 ng reactions. Second, although
methylation levels were relatively conserved and showed
little deviation in the hypomethylated (beta value <0.3)
and hypermethylated (>0.7) regions, considerable devia-
tions were found in the middle range of DNA methyla-
tion levels. These findings were not platform-dependent
results, as the independent pyrosequencing analysis
R=0.950 R=0.902
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Figure 7 Effect of averaging independently analyzed data of whole genome amplification (WGA) products. (a) Scatter plot of beta values
between the reference sample and averaged WGA products. (b) Beta value differences of averaged WGA products. The absolute beta value
difference between average WGA product and the reference sample was calculated for each probe. Values are mean and standard deviation.
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is consistent with previous examinations of several rep-
resentative CpG sites [12-14]. Third, given the nature of
random amplification deviations, averaging the multiple
WGA products considerably reduces the deviation.
Averaging three WGA products of 10 ng of bisulfite-
modified DNA showed better results with regard to beta
value difference in the middle range of methylation
levels as compared with WGA product of 50 ng of
bisulfite-modified DNA (Figure 7).
In terms of clinical settings, researchers must be cau-
tious when using WGA-based products for the detection
of subtle methylation differences, which are often
required for case–control studies of common diseases.
There are several requirements for such an application:
(1) the expected methylation difference should be rela-
tively large between groups; (2) the use of a sufficient
amount of bisulfite-modified DNA for WGA; and
(3) preparation of independent WGA replicates when-
ever possible. Practically, pooling the independent WGA
reactions is expected to be effective to reduce the devia-
tions. One alternative approach would be to treat themethylation level as a categorical variable. For example,
when we categorized methylation levels of the reference
sample as hypomethylation (beta value <0.3) and hyper-
methylation (beta value >0.7), 94% and 92% of the hypo-
methylated and 92% and 83% of the hypermethylated
probes were correctly detected in WGA product of 50
and 10 ng of bisulfite-modified DNA, respectively (data
not shown).
In this study, we employed the MDA-based WGA
method. Alternative WGA would be the primer exten-
sion preamplification (PEP)-based method [16]. As PEP
involves PCR reaction by DNA polymerase, MDA is
believed to produce more unbiased amplified products
[17]. However, a previous study reported that both
methods provided comparable results when bisulfite-
modified DNA was used as template [13]. One major
drawback of MDA-based method would be the insuffi-
cient amplification from severely degraded DNA tem-
plate [11]. As bisulfite modification causes DNA
degradation, low amount of input DNA will be resulted
in the failure of unbiased amplification. Therefore, im-
proving the bisulfite modification method, which prevents
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steps for further reduction of input DNA.Conclusions
WGA of bisulfite-modified DNA may serve as a valuable
tool for epigenetics research in the clinical medicine, al-
though careful experimental design and data interpret-
ation will be required.Methods
DNA sample
This study was approved by the ethics committee at the
University of Tokyo Hospital. Genomic DNA was
extracted from peripheral blood of an adult Japanese fe-
male by using a standard phenol-chloroform extraction.
Quality and integrity was assessed by optical density
(OD) measurement and gel electrophoresis. Quantity of
genomic DNA was measured using a Qubit dsDNA BR
assay kit (Life Technologies, Carlsbad, Califolnia, USA)
with a Qubit fluorometer (Life Technologies).Bisulfite modification and purification
Sodium bisulfite modification of genomic DNA was per-
formed with an EpiTect Bisulfite kit (Qiagen, Venlo,
Netherlands), according to the manufacturer’s instruc-
tions. The quantity of bisulfite-modified DNA was mea-
sured using Qubit ssDNA assay kit (Life Technologies)
with a Qubit fluorometer.Whole genome amplification of bisulfite-modified DNA
WGA of bisulfite-modified DNA was performed using
EpiTect Whole Bisulfitome kit (Qiagen), according to
the manufacturer’s instructions. In brief, bisulfite-
modified DNA was amplified with a reaction buffer con-
taining phi29 DNA polymerase at 28 °C for 8 h. WGA
included three independent experiments. In each experi-
ment, the sample set contained 50 or 10 ng of bisulfite-
modified DNA and DDW as the negative control. In
performing WGA, UV-irradiation of all the equipment
successfully suppressed nonspecific amplification from
negative controls [18] (data not shown).Illumina Infinium assay
An Illumina Infinium HumanMethylation450 assay (Illu-
mina) was performed according to the manufacturer’s
protocol. The DNA methylation level was represented
as a beta value, which was calculated as the ratio of
fluorescent signal intensity of the methylated probe to
those of total (methylated and unmethylated) probes by
the GenomeStudio software (Illumina) with the default
settings. All data are publicly available (GSE39565).Data analysis
We used the detection P value, which estimates the con-
fidence that the signals from the target CpG probe are
above those from the negative control probes, and aver-
age signal intensities for methylation and unmethylation
probes were used to compensate for the quality of WGA
products. P values below 0.01 were considered to repre-
sent specific detection of the target CpG probes. Spear-
man’s correlation and principal component analysis were
performed with R (ver. 2.13.0; http://www.R-project.org/).
Hierarchical clustering analysis was performed by another
multidimensional analysis package (amap) implemented
in the R software package [19].
Pyrosequencing
DNA methylation levels of the selected CpG sites were
measured by PSQ 96MA (Qiagen), according to the
manufacturer’s instructions. Briefly, bisulfite-PCR prod-
uct using a biotin labeled primer was mixed with a bind-
ing buffer containing streptavidin-sepharose beads. The
reaction mixture was placed onto a MultiScreen-HV,
Clear Plate (Millipore, Billerica, Massachusetts, USA).
After applying the vacuum, the beads were treated with
a denaturation solution, and were suspended with an
annealing buffer containing a sequencing primer. The
mixture was transferred onto a PyroMark Q96 Plate
Low (Qiagen). Sequencing reaction was performed with
a PyroMark Gold Q96 Reagents Kit (Qiagen). The per-
centage of methylation was calculated using the allele
quantification algorithm of the PyroMark Q96 ID soft-
ware 2.5.8.15 (Qiagen). Primers were listed in Table S1
in Additional file 1. Detailed methods are available upon
request.
Additional file
Additional file 1: Table S1. Primers used in this study.
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